Research Article | Volume: 6, Issue: 1, January, 2016

Evaluation of the Pharmaceutical Quality of Different Brands of Ranitidine Tablets Manufactured in Bangladesh: A Pharmaceutical and Public Health Prospective

Md. Moklesur Rahman Sarker ,  Md. Salman Rashid,  Ali Asghar Raju,  Masud Rana,  Mohammed Faisal Bin Karim,  Rehana Akter,  Abu Nayem Md. Al-Noman Howlader,  Long Chiau Ming,  Nahlah Elkudssiah Ismail   
Md. Moklesur Rahman Sarker1 & 2, Md. Salman Rashid1, Ali Asghar Raju1, Masud Rana1, Mohammed Faisal Bin Karim1, Rehana Akter3, Abu Nayem Md. Al-Noman Howlader1, Long Chiau Ming4, Nahlah Elkudssiah Ismail2 & 5

1Department of Pharmacy, School of Science, Primeasia University, 9 Banani C/A, Dhaka-1213, Bangladesh.

2Faculty of Pharmacy, Lincoln University College, No. 2, Jalan Stadium SS 7/15, Kelana Jaya, 47301 Petaling Jaya, Malaysia.

3Quality Assurance Department, Essential Drugs Company Ltd., Tejgaon I/A, Dhaka-1208, Bangladesh.

4Faculty of Pharmacy, Brain Degeneration and Therapeutics Group, Pharmaceutical and Life Sciences CoRe, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia.

5Clinical BioPharmaceutics Research Group (CBRG), Pharmaceutical and Life Sciences CoRe, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia.

Open Access   

Published:  Jan 26, 2016

DOI: 10.7324/JAPS.2016.60109
PDF [ 0.6 MB]
Request Permission
Share
Download Citation
Print
Download PDF
Abstract

Drug counterfeiting and production of substandard drug is a global problem. Substandard or counterfeit drugs are threat for the effective treatment of diseases and highly worsen the quality of life of patients. This study was aimed to assess the pharmaceutical quality of ranitidine hydrochloride tablets manufactured in Bangladesh. Tablets were collected from different parts of Bangladesh and quality parameters were evaluated according to the United States Pharmacopoeia and the British Pharmacopoeial methods. The potency of tablets was measured spectrophotometrically. Weight variation and disintegration time were performed according to pharmaceutical monographs. Among 43 brands tested, 8 failed to comply with the USP specification (active ingredient: 90±10%) due to containing of less amount of ranitidine of which 6 brands were spurious and 2 were substandard in nature. Two brands did not comply with the specification for weight variation of tablets whereas all brands passed disintegration time test. The findings clearly demonstrate the production of substandard ranitidine tablets in Bangladesh. The drug control authority of Bangladesh should take effective steps to prevent the production of substandard drugs to secure public health.


Keyword:     Ranitidine Spectrophotometric analysis Disintegration time Quality of drugs Substandard and Counterfeit drugs Spurious drugs Bangladesh.

Citation:

Sarker MMR, Rashid MS, Raju AA, Rana M, Karim MFB, Howlader ANMAN, Ming LC, Ismail NE. Evaluation of The Pharmaceutical Quality of Different Brands of Ranitidine Tablets Manufactured in Bangladesh: A Pharmaceutical And Public Health Prospective. J App Pharm Sci, 2016; 6 (01): 055-061.

Copyright:The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
HTML Full Text

Reference

Article Metrics
367 Views 30 Downloads 397 Total

Year

Month

Related Search

By author names